Unicycive Therapeutics, Inc.
$5.73▲ 8.52%(+$0.45)
TickerSpark Score
49/100
▌ Weak
60
Valuation
20
Profitability
60
Growth
76
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNCY research report →
52-Week Range40% of range
Low
$3.71
Current
$5.73
High
$8.74
Company Overviewwww.unicycive.com
About the company
Unicycive Therapeutics, Inc. is a U. S.
- CEO
- Shalabh K. Gupta
- IPO
- 2021
- Employees
- 22
- HQ
- Los Altos, CA, US
Price Chart
+23.49% · this period
Valuation
- Market Cap
- $123.15M
- P/E
- -2.80
- P/S
- 0.00
- P/B
- 36.33
- EV/EBITDA
- -2.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.18%
- ROIC
- -77.54%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,555,000 · 27.70%
- EPS
- $-1.67 · 70.18%
- Op Income
- $-29,517,000
- FCF YoY
- -9.40%
Performance & Tape
- 52W High
- $8.74
- 52W Low
- $3.71
- 50D MA
- $7.44
- 200D MA
- $6.27
- Beta
- 1.73
- Avg Volume
- 1.34M
Get TickerSpark's AI analysis on UNCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Form 4 · Filings
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Gupta Shalabh K. | other | 762,200 |
| May 14, 26 | Kenkare-Mitra Sara | other | 42,100 |
| May 14, 26 | Kenkare-Mitra Sara | other | 84,200 |
| May 14, 26 | Jermasek Douglas | other | 169,500 |
| May 14, 26 | Gupta Pramod | other | 169,500 |
| May 14, 26 | Townsend John | other | 169,500 |
| May 14, 26 | Laumas Sandeep | other | 42,100 |
| May 14, 26 | Laumas Sandeep | other | 84,200 |
| Aug 25, 25 | Aggarwal Gaurav | other | 652,900 |
| Aug 25, 25 | Aggarwal Gaurav | sell | 3,199.21 |
Coverage · UNCY
Our UNCY coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on UNCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UNCY report →Internal Compare
Similar companies
Peers in the same neighborhood.
CAMP▲2.07%
CAMP4 Therapeutics Corporation
$4.43
VXRT▲4.92%
Vaxart, Inc.
$0.64
RPTX▲0.00%
Repare Therapeutics Inc.
$2.65
BMEA▲3.68%
Biomea Fusion, Inc.
$1.41
IMUX▼0.07%
Immunic, Inc.
$14.80
ACRV▼0.58%
Acrivon Therapeutics, Inc. Common Stock
$1.72
PMVP▼1.61%
PMV Pharmaceuticals, Inc.
$1.22
RLMD▼1.72%
Relmada Therapeutics, Inc.
$6.28